Characteristics of lipid spectrum and functional liver tests in patients with nonalcoholic liver steatosis depending on degree of obesity during menopause

Abstract

Objective. To study the blood lipid spectrum and functional liver tests in women with nonalcoholic liver steatosis (NALS) depending on the degree of obesity during menopause.

Materials and methods. Seventy patients with NALS and obesity (NALS-O-M) in menopause with the mean age of 49,9 ± 1,1 years including 24 with increased body mass index (BMI), 20 – with the degree 1 obesity, 18 – the degree 2 obesity and 8 – the degree 3 obesity were examined. The control group involved 30 practically healthy women in menopause without obesity. Blood serum cytolysis, cholestasis and lipid spectrum indicators were studied in both groups.

Results. According to the results of biochemical investigation, in the group of patients with NALS-O-M syndrome no cytolysis was observed. In case of marked obesity, cholestasis syndrome by the blood alkaline phosphatase level was identified. Lipid spectrum in patients with NALS-O-M statistically significantly differed from the control: hypercholesterinemia, hypertriglyceridemia, increase in the low- and very low-density lipoproteins as well as calculated index of atherogeneity with decrease in the high-density lipoproteins fraction was registered.

Conclusions. A pronounced obesity causes the cholestasis syndrome with an increase in the blood alkaline phosphatase level. Dyslipidemia of different degree of manifestation is registered in all patients with steatosis and obesity during menopause, being more marked in patients with the degree 2–3 obesity.

Keywords

nonalcoholic liver steatosis / dyslipidemia / menopause

References

[1] Drapkina O.M., Ivashkin V.T. Epidemiological features of non-alcoholic fatty liver disease in Russia (results of an open multicenter prospective follow-up study DIREGL 01903). Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii 2014; 4 (24): 32–38 (in Russian).

[2] Драпкина О.М., Ивашкин В.Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (результаты открытого многоцентрового проспективного исследования-наблюдения DIREGL 01903). Российский журнал гастроэнтерологии, гепатологии, колопроктологии 2014; 4 (24): 32–38.

[3] Li Z. T., Ji F., Han X,W., Wang L., Yue Y.Q., Wang Z.G. The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients with Hypertension. Journal of Clinical Gastroenterology 2018; 8 (52): 685–690.

[4] Li Z.T., Ji F., Han X.W., Wang L., Yue Y.Q., Wang Z.G. The Role of Gastroesophageal Reflux in Provoking High Blood Pressure Episodes in Patients with Hypertension. Journal of Clinical Gastroenterology 2018; 8 (52): 685–690.

[5] Younossi Z.M., Koenig А.В., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 1 (64): 73–84.

[6] Lazebnik L.B., Golovanova U.V., Turkina S.V. Non-alcoholic fatty liver disease in adults: clinic, diagnosis, treatment. Recommendations for therapists, the third version. Eksperimental'naya i klinicheskaya gastroenterologiya 2021; 1 (1): 4–52 (in Russian).

[7] Лазебник Л. Б., Голованова У.В., Туркина С.В. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология 2021; 1 (1): 4–52.

[8] Krolevets T. S., Livzan M.A. Clinical and laboratory markers for predicting liver fibrosis in individuals with non-alcoholic fatty liver disease. Eksperimental'naya i klinicheskaya gastroenterologiya 2018; 7 (155): 43–51 (in Russian).

[9] Кролевец Т.С., Ливзан М.А. Клинико-лабораторные маркеры прогнозирования фиброза печени у лиц с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология 2018; 7 (155): 43–51.

[10] Gulyaeva I.L., Miftakhova A.M., Bulatova I.A., Kurtsev B.V. Pathogenetic justification of the use of Dzhigurda Procumbens for the prevention of the development of non-alcoholic liver steatosis (experimental study). Mezhdunarodnyy nauchno-issledovatel'skiy zhurnal 2021; 8 (110): 100–105, available at: https:// research-journal.org/wp-content/uploads/2021/ 08/8-110-2.pdf.

[11] Гуляева И.Л., Мифтахова А.М., Булатова И.А., Курцев Б.В. Патогенетическое обоснование применения «Джинуры Прокумбенс» для профилактики развития неалкогольного стеатоза печени (экспериментальное исследование). Международный научно-исследовательский журнал 2021; 8 (110): 100–105, available at: https://research-journal.org/wp-content/uploads/2021/08/8-110-2.pdf

[12] Miftakhova A.M., Gulyaeva I.L., Bulatova I.A. Dynamics of functional liver tests on an experimental animal model against the background of taking Jinuri Procumbens. Nauka i innovatsii-sovremennye kontseptsii: sbornik nauchnykh statey po itogam raboty mezhdunarodnogo nauchnogo foruma 2021; 48–51 (in Russian).

[13] Мифтахова А.М., Гуляева И.Л., Булатова И.А. Динамика функциональных печеночных тестов на экспериментальной модели животных на фоне приема Джинури Прокумбес. Наука и инновации-современные концепции: сборник научных статей по итогам работы международного научного форума 2021; 48–51.

[14] Miftakhova A.M., Gulyaeva I.L., Bulatova I.A. The effect of the aqueous extract of Jinura Procumbens on the lipid spectrum against the background of experimental liver steatosis. Vysshaya shkola: nauchnye issledovaniya: sbornik mezhvuzovskogo mezhdunarodnogo kongressa 2021; 92–96 (in Russian).

[15] Мифтахова А.М., Гуляева И.Л., Булатова И.А. Влияние водного экстракта «Джинуры Прокумбенс» на липидный спектр на фоне экспериментального стеатоза печени. Высшая школа: научные исследования: сборник межвузовского международного конгресса 2021; 92–96.

RIGHTS & PERMISSIONS

Bulatova I.A., Sobol A.A., Gulyaeva I.L.